首页> 美国卫生研究院文献>Globalization and Health >Canada and access to medicines in developing countries: intellectual property rights first
【2h】

Canada and access to medicines in developing countries: intellectual property rights first

机译:加拿大与发展中国家获得药品的途径:知识产权优先

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Canadian reports have recommended that health as a human right must be Canada’s overarching global commitment and that the primacy of human rights should be prioritized over other elements of international law including international trade and investment law as it applies to access to pharmaceuticals. This paper uses a series of case reports to examine Canada’s commitment to this goal. Specifically it examines cases where improved access has been in conflict with increased intellectual property rights. The 6 cases are: Canada’s position when 39 pharmaceutical companies took South Africa to court in 1998 over its legislation to allow parallel importation of patented medicines and to regulate the price of medications; the stance that Canada took in the negotiations around the Doha Declaration in 2001; the passage of Canada’s Access to Medicines Regime in 2004 and subsequent attempts to amend the legislation in 2011 and 2012; Canada’s involvement in the final declaration at the United Nations High-Level meeting on non-communicable diseases in 2012; Canada’s views about the terms in the Anti-Counterfeiting Trade Agreement as expressed in 2009; and Canada’s 2013 position on the extension of the exemption for least developed countries from having to comply with the terms of the Trade Related Aspects of Intellectual Property Rights Agreement. In the first case Canada was neutral but in the remaining 5 cases Canada prioritized intellectual property rights over access. This position is consistent with how Canada has acted around domestic issues involving intellectual property rights for pharmaceutical products. Canada has supported strengthened rights despite the fact that their touted benefits have not been realized either domestically or in developing countries. As a result Canada has failed in its humanitarian duty to protect the human right to health in the form of safe and low cost medicines for the people in developing countries.
机译:加拿大的报告建议,健康作为一项人权必须是加拿大的首要全球承诺,人权的优先地位应优先于国际法的其他要素,包括适用于获取药品的国际贸易和投资法。本文使用一系列案例报告来研究加拿大对这一目标的承诺。具体来说,它研究了访问量增加与知识产权增加冲突的情况。这六起案件是:加拿大的立场,1998年有39家制药公司就其立法允许南非平行进口专利药品和规范药品价格的诉讼;加拿大在2001年围绕《多哈宣言》进行谈判的立场;加拿大于2004年通过了《药品获得许可制度》,并随后在2011年和2012年试图修改该法规;加拿大参与了2012年联合国非传染性疾病高级别会议的最终宣言;加拿大对2009年发表的《反假冒贸易协定》中条款的看法;加拿大在2013年的立场上,将最不发达国家的豁免范围扩大到必须遵守《与贸易有关的知识产权协议》的条款。在第一个案例中,加拿大是中立的,但在其余五个案例中,加拿大将知识产权置于获取之上。这一立场与加拿大在涉及药品知识产权的国内问题上采取的行动是一致的。尽管事实上,无论是在国内还是在发展中国家,尚未实现其吹捧的利益,但加拿大仍支持加强权利。结果,加拿大未能履行其人道主义义务,即以安全和廉价的药品形式为发展中国家的人民提供保护健康的人权。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号